Moreover, drugs selectively targeting CARM1-mediated BAF155 methylation may join the family of small molecule inhibitors targeting SWI/SNF complex assembly and function (56), and are expected to exhibit profound anti-cancer effects, while eliciting even fewer side-effects as compared to CARM1 inhibitors. This evidence concerns the gene SMARCA1 and cancer.